26.05.2021 • NewsCharles River

Charles River Acquires Vigene Biosciences

US CDMO Charles River Laboratories has entered into an agreement to buy Vigene Biosciences, a compatriot gene therapy CDMO specializing in viral vectors. The acquisition is expected to close at the beginning of the third quarter of 2021. The purchase price is likely to be $292.5 million in cash, but the transaction also includes contingent additional payments of up to $57.5 million based on future performance.

“The addition of Vigene Biosciences’ extensive gene therapy expertise will enable us to expand our comprehensive cell and gene therapy portfolio to span each of the major CDMO platforms – cell therapy, viral vector, and plasmid DNA production,” said Charles River’s chairman, president and CEO James Foster. “Our goal is to become our clients’ scientific partner of choice for advanced drug modalities from discovery and non-clinical development to cGMP manufacturing.”

Based in Rockville, Maryland, Vigene has expertise in adeno-associated virus cGMP production – the most commonly used delivery system for gene therapies – as well as for other major viral vectors, including lentivirus. The CDMO also offers high-quality, research grade and cGMP plasmid DNA, used in the development of viral vectors for gene-modified cell therapies, gene therapies and vaccine production.

Charles River expects Vigene to generate annual revenue of between $30 million and $35 million this year. According to Charles River, the addressable market for cell and gene therapy CDMO services, principally for cell therapy, plasmid DNA and viral vector production, is estimated at $2.5 billion globally and is forecast to grow at least 25% per year over the next five years.

The takeover of Vigene will also be highly complementary to Charles River’s existing gene therapy CDMO capabilities in Keele, UK, and Matfors, Sweden, which were acquired when it bought Cognate BioServices in March.

Author: Elaine Burridge, Freelance Journalist

US CDMO Charles River Laboratories has entered into an agreement to buy Vigene...
US CDMO Charles River Laboratories has entered into an agreement to buy Vigene Biosciences, a compatriot gene therapy CDMO specializing in viral vectors. The acquisition at an expected $292.5 million is expected to close at the beginning of the third quarter of 2021. (c) Vigene Biosciences

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.